XBiotech: Strong Upside Potential In Atopic Dermatitis And Hidradenitis Suppurativa

Intravenous administration of bermekimab showed compelling phase II data in hidradenitis suppurativa (HS). Bermekimab beat adalimumab …

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *